Back to today’s briefing

Story perspectives

Hope for Duchenne Patients Amidst Drug Access Struggles

5/20/2025

28 4

Summary

Story summary

EdiGene's LE051 RNA-editing drug shows early promise in enhancing motor function for Duchenne muscular dystrophy patients, igniting hope for families. In contrast, the Netherlands slips to 11th place in European drug access, leaving patients in limbo with extended wait times. Meanwhile, a determined mother in the UK fights for wider access to Brineura, a vital treatment for children battling CLN2 Batten disease.

1 of 1

Story summary

EdiGene's LE051 RNA-editing drug shows early promise in enhancing motor function for Duchenne muscular dystrophy patients, igniting hope for families. In contrast, the Netherlands slips to 11th place in European drug access, leaving patients in limbo with extended wait times. Meanwhile, a determined mother in the UK fights for wider access to Brineura, a vital treatment for children battling CLN2 Batten disease.